Results 141 to 150 of about 2,224,846 (160)

Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.

Int J Oncol, 2018
Zhang W, Cai X, Yu J, Lu X, Qian Q, Qian W.   +5 more
europepmc   +1 more source

Redox regulation of EGFR activation by thioredoxin reductase 3 drives resistance to EGFR inhibitors in triple-negative breast cancer. [PDF]

Cell Death Discov
Raninga PV, Raninga PV, Giner G, Sankarasubramanian S, Kalimutho M, Herold MJ, Weck A, Khanna KK.   +7 more
europepmc   +1 more source

Engineering microRNAs as multimodal cancer therapeutics. [PDF]

Mol Ther Nucleic Acids
Kang R, Tang D.
europepmc   +1 more source

Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer. [PDF]

Mol Ther Nucleic Acids
Intriago EM, Pal A, Ojha A, Cui M, Pesselev IY, Coant N, Guo I, Haley J, Ju J.   +8 more
europepmc   +1 more source

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib [PDF]

Journal of Thoracic Oncology, 2011
IntroductionMesenchymal status is related to “inherent resistance” to gefitinib or erlotinib in non-small cell lung cancer without epidermal growth factor receptor(EGFR) mutations.
Tetsuya Mitsudomi, Kenichi Suda
exaly   +2 more sources

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients

Cancers, 2019
Previously, we reported that nicotine reduces erlotinib sensitivity in a xenograft model of PC9, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-sensitive non-small-cell lung cancer cell line.
Tadaaki Yamada, Junji Uchino, Tamiya Nobuyo   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma

Cancers, 2022
Bei Qing, Yiqun Jiang, Shiyao Jiang
exaly  

Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed

Journal of Thoracic Oncology, 2013
Tomonori Hirashima, Shinzoh Kudoh
exaly  

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

Head and Neck, 2014
John V Heymach, Mitchell Frederick, Jeong Hun Hah   +2 more
exaly  

[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice.

Nuclear Medicine and Biology, 2017
Severin Mairinger, Christine Pirker, Thomas Wanek   +2 more
exaly